Literature DB >> 25039430

Minimally invasive access for central extracorporeal life support: how we do it.

Alexander Weymann1, Anton Sabashnikov, Nikhil P Patil, Prashant N Mohite, Bartlomiej Zych, Diana Garcia Saez, Aron-Frederik Popov, Andre R Simon.   

Abstract

Central extracorporeal life support (ECLS) is an effective treatment method of cardiogenic shock patients with or without lung failure. However, complications like infection and bleeding are common. The classical implantation approach requires full sternotomy, mobilization of the heart, with the well-known risks of bleeding and mediastinal infections. We present our minimally invasive technique for central ECLS through a nonsternotomy incision. Minimized right-sided thoracotomy is performed. Flexible arterial and venous cannulas are tunneled toward the right thoracotomy incision through the eighth intercostal space. A sewing ring is secured to the right atrium and a tube graft is anastomosed to the ascending aorta. Following full-dose heparinization, the arterial cannula is inserted with the tip into the vascular graft of the ascending aorta and the venous cannula via the ring into the right atrium. After meticulous deairing, the central ECLS is set at full flow.
Copyright © 2014 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Keywords:  Extracorporeal life support; Minimally invasive surgery

Mesh:

Year:  2014        PMID: 25039430     DOI: 10.1111/aor.12344

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  1 in total

1.  Extracorporeal life support with left ventricular decompression-improved survival in severe cardiogenic shock: results from a retrospective study.

Authors:  Bastian Schmack; Philipp Seppelt; Alexander Weymann; Christina Alt; Mina Farag; Rawa Arif; Andreas O Doesch; Philip W Raake; Klaus Kallenbach; Ashham Mansur; Aron-Frederik Popov; Matthias Karck; Arjang Ruhparwar
Journal:  PeerJ       Date:  2017-09-29       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.